


**Product Name** : BGB-16673  
**Cat. No.** : PC-21567  
**CAS No.** : 2736508-94-2  
**Molecular Formula** : C<sub>48</sub>H<sub>55</sub>N<sub>11</sub>O<sub>4</sub>  
**Molecular Weight** : 850.04  
**Target** : PROTAC  
**Solubility** : 10 mM in DMSO



## Biological Activity

Catadegbrutinib (BGB-16673) is an orally available heterobifunctional **BTK PROTAC** degrader that binds to BTK and E3 ligase, degrades wildtype BTK and multiple mutant forms via ubiquitination.

BGB-16673 exhibits high potency on clinically relevant BTK mutants resistant to covalent and non-covalent BTK inhibitors in cancer cells in vitro.

BGB-16673 drives complete tumor regression of lymphoma xenograft models expressing wildtype or BTK mutations resistant to covalent and non-covalent inhibitors.

BGB-16673 presents longer duration of response than BTK inhibitors in BTK wildtype and C481S mutant-expressing lymphoma xenograft models.

## References

John F. Seymour, et al. **Blood** (2023) 142 (Supplement 1): 4401.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com